StockStory.org on MSN
ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results , with sales up 4.8% year on year to $1.09 billion. The ...
Illumina () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smart ...
3don MSN
Illumina forecasts $4.52B-$4.62B 2026 revenue and $5.15-$5.30 EPS while scaling NovaSeq X supply
Q1 2026 Management View Jacob Thaysen opened by saying, "We are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range," adding that performance reflected ...
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results